Contact
searchSearch
HMP Global
Login

News

a young woman lies awake in bed
News
Adolescent Insomnia and Daytime Sleepiness Linked to Depression Risk
06/25/2026
Maria Mantas
A 3-year longitudinal study found that insomnia, excessive daytime sleepiness (EDS), and their co-occurrence were associated with increased risk of depression. 
A 3-year longitudinal study found that insomnia, excessive daytime sleepiness (EDS), and their co-occurrence were associated with increased risk of depression. 
A 3-year longitudinal study...
06/25/2026
Psych Congress Network
A man with depression holds his head in his hands
Research Summary
Navacaprant Fails Late-Stage MDD Trials
06/22/2026
Brionna Mendoza
Navacaprant, a kappa opioid receptor antagonist for major depressive disorder treatment, failed to show statistically significant efficacy in two phase 3 trials.
Navacaprant, a kappa opioid receptor antagonist for major depressive disorder treatment, failed to show statistically significant efficacy in two phase 3 trials.
Navacaprant, a kappa opioid...
06/22/2026
Psych Congress Network
a man surrounded by alcohol and other substances on a table
News
Reduced Stimulant Use Outcomes May Reveal Treatment Effects Missed by Abstinence Measures
06/18/2026
Maria Mantas
Evaluating reduced stimulant use rather than complete abstinence outcomes in patients with stimulant use disorder could provide additional insight into treatment efficacy.
Evaluating reduced stimulant use rather than complete abstinence outcomes in patients with stimulant use disorder could provide additional insight into treatment efficacy.
Evaluating reduced stimulant use...
06/18/2026
Psych Congress Network
Viloxazine MOA Study image
News
New Study Clarifies Multimodal Mechanism of Viloxazine in ADHD
06/11/2026
New research further characterizes viloxazine’s pharmacologic profile, supporting a multimodal mechanism involving norepinephrine transporters and serotonin receptors.
New research further characterizes viloxazine’s pharmacologic profile, supporting a multimodal mechanism involving norepinephrine transporters and serotonin receptors.
New research further...
06/11/2026
Psych Congress Network
Weight scale and tape measure
News
Retrospective Cohort Study Explores Long-Term Growth Outcomes Following Pediatric Methylphenidate Use
06/11/2026
A retrospective cohort study examined the association between pediatric ADHD, methylphenidate exposure, and adult BMI and height outcomes. The findings suggest that ADHD—particularly when treated with methylphenidate—may be associated with...
A retrospective cohort study examined the association between pediatric ADHD, methylphenidate exposure, and adult BMI and height outcomes. The findings suggest that ADHD—particularly when treated with methylphenidate—may be associated with...
A retrospective cohort study...
06/11/2026
Psych Congress Network
a woman scrolls on her phone while laying in bed
News
US Study Finds No Link Between AI Use and Depression
05/28/2026
Maria Mantas
A recent target trial emulation found no evidence of a causal relationship between frequent AI use and increased depressive symptoms among adults.
A recent target trial emulation found no evidence of a causal relationship between frequent AI use and increased depressive symptoms among adults.
A recent target trial emulation...
05/28/2026
Psych Congress Network
A clinician in the lab pulls a psilocybin mushroom from a bag using tweezers major depressive disorder mdd treatment
News
Single-Dose Psilocybin Rapidly Improves MDD Symptoms, RCT Finds
05/19/2026
Brionna Mendoza
A single dose of psilocybin was associated with a significant reduction in depressive symptoms within 2 days of administration in patients with major depressive disorder (MDD), according to randomized control trial results.
A single dose of psilocybin was associated with a significant reduction in depressive symptoms within 2 days of administration in patients with major depressive disorder (MDD), according to randomized control trial results.
A single dose of psilocybin was...
05/19/2026
Psych Congress Network
injection for schizophrenia treatment
News
Once-Monthly Aripiprazole Demonstrates Favorable Benefit–Risk Profile in Schizophrenia Treatment
05/14/2026
Maria Mantas
Once-monthly aripiprazole 400 mg (AOM 400) demonstrated a favorable risk-benefit profile as an acute and long-term maintenance treatment in patients with schizophrenia.
Once-monthly aripiprazole 400 mg (AOM 400) demonstrated a favorable risk-benefit profile as an acute and long-term maintenance treatment in patients with schizophrenia.
Once-monthly aripiprazole 400 mg...
05/14/2026
Psych Congress Network
A man with depression holds his head in his hands
News
Lumateperone Tops Efficacy in Adjunctive Treatment for MDD, Review Finds
05/12/2026
Brionna Mendoza
A new systematic review and network meta-analysis published in JAMA Psychiatry evaluated the comparative efficacy and acceptability of the 5 FDA-approved atypical antipsychotics used as adjunctive therapy for major depressive disorder (MDD).
A new systematic review and network meta-analysis published in JAMA Psychiatry evaluated the comparative efficacy and acceptability of the 5 FDA-approved atypical antipsychotics used as adjunctive therapy for major depressive disorder (MDD).
A new systematic review and...
05/12/2026
Psych Congress Network
A boy eating junk food while using a laptop computer
News
The Link Between Ultra-Processed Foods and ADHD
05/12/2026
Recent findings point to a possible link between ADHD and higher intake of ultra-processed foods.
Recent findings point to a possible link between ADHD and higher intake of ultra-processed foods.
Recent findings point to a...
05/12/2026
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Insights
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use